Wave Life Sciences Q3 net loss widens 15% to $61.91 million; Q3 revenue rises 73% to $13.16 million
Bitget2026/10/27 11:32- Wave Life Sciences’ third-quarter 2026 net loss widened 15% year over year to $61.91 million.
- Revenue climbed 73% year over year to $13.16 million.
- Cash, cash equivalents and marketable securities totaled $431 million at September 30, with operations funded into the third quarter of 2028.
- Planning is underway for WVE-006’s two-year AATD registrational trial, including a one-year interim analysis supporting potential accelerated approval.
- The WVE-007 combination trial with tirzepatide is underway, with a post-incretin maintenance trial targeted to begin in the fourth quarter of 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
EIA expects Brent crude spot prices to remain at $100 per barrel for the rest of the year and raises the average price forecasts for this year and next.
The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.
Moody’s and Chainlink Complete Cross-Chain Credit Ratings Distribution Pilot
Crypto prices
More
